The Korean Journal of Gastroenterology (대한소화기학회지)

The Korean Society of Gastroenterology (대한소화기학회)
권호 표지

Therapeutic Effect of Low-Dose Omeprazole vs. Standard-Dose Ranitidine in Mild to Moderate Reflux Esophagitis

경도-중등도의 역류성 식도염에서 저용량 오메프라졸과 표준 용량 라니티딘의 치료 효과

Kim, Jae-Woo;Kim, Hyun-Soo;Lee, Dong-Ki;Suk, Ki-Tae;Kim, Jung-Min;Baik, Soon-Koo;Kwon, Sang-Ok;Cho, Mee-Youn
김재우;김현수;이동기;석기태;김정민;백순구;권상옥;조미연

  • Published : 20040300
⟨ Previous Next ⟩

Abstract

Background/Aims: Proton pump inhibitors (PPI) and H2-receptor antagonists (H2RA) are commonly prescribed for the treatment of mild to moderate reflux esophagitis (MMRE). There remains great controversy in their usefulness as the first choice and the appropriateness. We prospectively compared the efficacy and safety of the 8-week low-dose PPI vs. standard-dose H2RA in MMRE. Methods: One hundred patients with MMRE were randomized to receive either low-dose of omeprazole (L-OMP: 10 mg, q.d.) or standard-dose of ranitidine (S-H2RA: 150 mg, b.i.d.) for 8 weeks. The H. pylori status using rapid urease test, histological examination and culture, reflux esophagitis (RE) grading, gastrointestinal symptoms using 4-point scale, adverse event and the standard laboratory examination were assessed at baseline and 8-week end point of therapy. Results: Improvement rate of RE [intention to treat (n=82)/per protocol (n=72)] were shown in 69.1%/63.9% for L-OMP and 65.0%/63.9% for S-H2RA group (p=0.697, p=1.000). Complete healing rates of RE were 54.7%/50.0% for L-OMP and 42.5%/41.7% for S-H2RA. No significant difference in healing rate, the rapidity of symptom resolution, adverse events, and laboratory monitoring was found between the two groups. Conclusions: The low-dose omeprazole therapy produced similar healing rates and safety in the treatment of MMRE. In addition, L-OMP is advantageous in its once-a-day dosing and might be an alternative to S-H2RA, especially in Korean patients with MMRE.

Keywords

References

  1. Kahrilas PJ, Quigley EM. Clinical esophageal pH recording: a technical review for practice guideline development. Gastroenterology 1996;110:1982-1996. https://doi.org/10.1053/gast.1996.1101982
  2. Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995;333:1106-1110. https://doi.org/10.1056/NEJM199510263331703
  3. Harris RA, Kuppermann M, Richter JE. Prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis of maintenance proton pump inhibition. Am J Med 1997;102:78-88. https://doi.org/10.1016/S0002-9343(96)00301-4
  4. Kawano S, Murata H, Tsuji S, et al. Randomized comparative study of omeprazole and famotidine in reflux esophagitis. J Gastroenterol Hepatol 2002;17:955-959. https://doi.org/10.1046/j.1440-1746.2002.02785.x
  5. Yun HR, Jung HY, Park HJ, Bae SC. Cost-effectiveness analysis of proton pump inhibitors and ranitidine in the treatment of gastroesophageal reflux disease. Korean J Med 2002;62:504-512.
  6. Marks RD, Richter JE, Rizzo J, et al. Omeprazole versus H2-receptor antagonists in treating patients with peptic stricture and esophagitis. Gastroenterology 1994;106:907-915.
  7. Dent J, Yeomans ND, Mackinnon M, et al. Omeprazole vs ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety. Gut 1994;35:590-598. https://doi.org/10.1136/gut.35.5.590
  8. Dent J, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management-the Genval Workshop Report. Gut 1999;44(suppl 2):1S-16S.
  9. Klinkenberg-knol EC, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000;118:661-669. https://doi.org/10.1016/S0016-5085(00)70135-1
  10. Smith PM, Kerr GD, Cockel R, et al. A comparison of omeprazole and ranitidine in prevention of recurrence of benign esophageal stricture. Restore Investigator Group. Gastroenterology 1994;107:1312-1318.
  11. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997;112:1798-1810. https://doi.org/10.1053/gast.1997.v112.pm9178669
  12. DeVault KR, Castell DO. Current diagnosis and treatment of gastroesophageal reflux disease. Mayo Clin Proc 1994;69:867-876. https://doi.org/10.1016/S0025-6196(12)61790-X
  13. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The practice parameters committee of the American College of Gastroenterology. Am J Gastroenterol 1999;94:1434-1442. https://doi.org/10.1111/j.1572-0241.1999.1123_a.x
  14. Lind T, Havelund T, Carlsson R, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997;32:974-979. https://doi.org/10.3109/00365529709011212
  15. Kim YS, Song CW, Kim YH, et al. Effects of ranitidine (300 mg) and omeprazole (10, 20 mg) on gastroesophageal reflux and intragastric pH in healthy subjects. Korean J Gastrointest Motil 2000;6:206-213.
  16. Hallerback B, Unge P, Carling L, et al. Omeprazole or ranitidine in long-term treatment of reflux esophagitis. The Scandinavian Clinics for United Research Group. Gastroenterology 1994;107:1305-1311.
  17. Labenz J, Blum AL, Bayerdorffer E, Mening A, Stolte M, Borsch G. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997;112:1442-1447. https://doi.org/10.1016/S0016-5085(97)70024-6
  18. Koike T, Ohara S, Sekine H, et al. Helicobacter pylori infection inhibits reflux esophagitis by inducing atrophic gastritis. Am J Gastroenterol 1999;94:3468-3472. https://doi.org/10.1111/j.1572-0241.1999.01593.x
  19. Rhee PL. Association between Helicobacter pylori and gastroesophageal reflux disease. Korean J Gastroenterol 2003; 42:179-182.
  20. Soga T, Matsuura M, Kodama Y, et al. Is a proton pump inhibitor necessary for the treatment of lower-grade reflux esophagitis? J Gastroenterol 1999;34:435-440.